Abacavir/3TC vs. Tenofovir/FTC: Interim Results from ACTG 5202
An interim analysis from ACTG 5202 suggests that abacavir/3TC is not as effective as tenofovir/FTC in reducing viral load among treatment-naive patients with high viral loads (100,000 or more copies/mL) at baseline.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)
